![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaU1GIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--0d4e0e8098d1a0615ec73c3cbdb44963ee8d009e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Stargazer%20Pharmaceuticals.png)
Qlaris Bio
Qlaris is developing a targeted novel mechanism of episcleral venous pressure to treat underserved glaucoma patients.
Website
qlaris.bioPartner
Wende HuttonInvestment
Series A
Qlaris is developing a targeted novel mechanism of episcleral venous pressure to treat underserved glaucoma patients.
Series A